- Relieves osteoarthritis pain
- Key factor in several biological pathways including methylation reactions, glutathione formation and glutathione S-transferase activity
- Enteric coating protects SAMe degradation caused by stomach acid, allowing for significantly improved intestinal absorption.
- 200 mg SAMe per tablet for flexible dose titration
- SAMe is produced through a natural fermentation process that produces higher active ingredients than synthetic variations.
- Suitable for vegetarians
S-Adenosyl-L-Methionine (SAMe) has several essential physiological functions and is the common thread between three key metabolic pathways. Well recognized as a unique methyl donor for over 100 biological reactions, including DNA methylation. It also links methylation to the synthesis of polyamines (necessary for cell survival and growth) and transsulfuration, which is responsible for the production of cysteine, the limiting factor in glutathione synthesis. Its unique positioning within these crossed pathways explains its role as regulator of redox status, cellular metabolism, proliferation and apoptosis.
It has been clinically proven to relieve a number of conditions, including osteoarthritis, fibromyalgia, neurodegenerative diseases, depression and liver disease. For patients with major depressive disorder, SAMe has been shown to be effective not only compared to standard antidepressants, but also for non-responders to selective serotonin reuptake inhibitors (SSRIs). It has also been shown to reduce the incidence of sexual dysfunction that commonly accompanies SSRI/SNRI treatment. SAMe has also shown effectiveness for osteoarthritis comparable to that of NSAIDs, including celecoxib. More importantly, this is likely due to an increase in cartilage formation, glutathione production, DNA methylation, and gene expression that contribute to its effectiveness, a stark contrast to pharmaceutical painkillers. Research also suggests benefit for neurodegenerative diseases and potentially for improving endothelial function.
Thanks for subscribing!
This email has been registered!